Ryanodex FDA Approval History
Last updated by Judith Stewart, BPharm on March 2, 2021.
FDA Approved: Yes (First approved July 22, 2014)
Brand name: Ryanodex
Generic name: dantrolene
Dosage form: Injectable Suspension
Company: Eagle Pharmaceuticals, Inc.
Treatment for: Malignant Hyperthermia
Ryanodex (dantrolene) is a skeletal muscle relaxant in a concentrated formulation for the treatment of malignant hyperthermia.
Development timeline for Ryanodex
| Date | Article |
|---|---|
| Jul 23, 2014 | Approval FDA Approves Ryanodex for the Treatment of Malignant Hyperthermia |
| Mar 20, 2014 | NDA for Orphan Drug Ryanodex Accepted By FDA |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
